Magnum: fourth-quarter sales fell short of expectations, with volumes down 3%, blame anti-obesity drugs?

Jefferies analyst David Hayes told the Financial Times that Magnum’s financial results ‘rekindle concerns’ about the structural risks of anti-obesity drugs for the ice cream category.

The separation from Unilever has made it more difficult to read the group’s results. On the GLP-1 drugs read here.